Bio-Rad Laboratories (BIO) EBT Margin (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of EBT Margin data on file, last reported at 116.5% in Q1 2026.

• On a quarterly basis, EBT Margin fell 13075.0% year-over-year to 116.5% in Q1 2026; TTM through Mar 2026 was 8.58%, a 11681.0% increase from a year earlier, with the FY2025 full-year figure at 38.54%, up 12981.0% from the prior year.
• EBT Margin for Q1 2026 stood at 116.5%, down from 134.05% in the prior quarter.
• Over the last five years, EBT Margin for BIO reached as high as 149.45% in Q4 2022 and fell as low as 623.92% in Q1 2022.
• Historically, EBT Margin has averaged 66.76% across 5 years, with a median of 12.53% in 2023.
• Across the five-year window, EBT Margin slumped 80240 bps in 2022 and jumped 63645 bps in 2023, its largest moves.
• Year by year, EBT Margin stood at 149.45% in 2022, then slumped by 58 bps to 62.89% in 2023, then slumped by 317 bps to 136.16% in 2024, then jumped by 198 bps to 134.05% in 2025, then sank by 187 bps to 116.5% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 116.5% in Q1 2026, 134.05% in Q4 2025, and 66.02% in Q3 2025.